Orphanin FQ potentiates formalin-induced pain behavior and antagonizes morphine analgesia in rats

doi:10.1016/S0304-3940(97)00704-0

Neuroscience Letters

Volume 235, Issues 1–2, 10 October 1997, Pages 37-40

https://doi.org/10.1016/S0304-3940(97)00704-0 Get rights and content

Abstract

The present study was designed to observe the effect of orphanin FQ (OFQ, also known as `nociceptin'), a newly-discovered neuropeptide, on pain behavior and morphine analgesia evaluated by formalin test in rats. It was found that intracerebroventricular (i.c.v.) injection of 0.1 μg OFQ had no effect on formalin-induced pain behavior; but 1, 5, 10 or 20 μg OFQ produced prolonged lifting, licking, biting or shaking of the affected paw with higher pain scoring in dose dependent manner. Repeated i.c.v. injection of antisense olignucleotide (ASO) complementary to OFQ receptor but not mismatch olignucleotide (MSO) resulted in the decrease of pain behavior; in such circumstances, OFQ showed no enhancing effect on formalin nociception. OFQ (0.1 or 1 μg, i.c.v.) significantly attenuated morphine analgesia and ASO could validly antagonize the effect of it. Pretreatment with MSO had no such effect. The present results suggest that OFQ enhances the pain behavior of rat and antagonizes morphine analgesia in formalin test.

Section snippets

Acknowledgements

This work was supported, in part, by the National Natural Science Foundation of China (39670901), Scientific and Technological Foundation of Shanghai (95XD14004), and `Qi-Ming-Xing' Plan for Young Scientists of Shanghai.

References (20)

D. Dubuisson et al.
The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats
Pain
(1977)
K.R. Gogas et al.
Inhibition of noxious stimulus-evoked pain behaviors and neuronal fos-like immunoreactivity in the spinal cord of the rat by supraspinal morphine
Pain
(1996)
J.S. Mogil et al.
Functional antagonism of μ, δ and κ-opioid antinociception by orphanin FQ
Neurosci. Lett.
(1996)
N.P. Murphy et al.
Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats
Neuroscience
(1996)
G.C. Rossi et al.
Naloxone sensitive orphanin FQ-induced analgesia in mice
Eur. J. Pharmacol.
(1996)
M. Sugimoto et al.
Involvement of medullary opioid-peptidergic and spinal noradrenergic systems in the regulation of formalin-induced persistent pain
Neuropharmacology
(1986)
M.J. Wick et al.
Isolation of novel cDNA encoding a putative membrane receptor with high homology to the cloned μ, δ and κ opioid receptors
Mol. Brain Res.
(1994)
M. Zimmermann
Ethical guidelines for investigations of experimental pain in conscious animals
Pain
(1983)
O.B. Famser et al.
Changes in nociception after lesions of descending serotoninergic pathways induced with 5,6-dihydroxytryptamine. Different effects in the formalin and tail-flick tests
Neuropharmacology
(1985)
A.R. Gintzler et al.
Nociceptin can modulate evoked enkephalin release from the myenteric plexus
Soc. Neurosci. Abstr.
(1996)

There are more references available in the full text version of this article.

Cited by (66)

Central N/OFQ-NOP Receptor System in Pain Modulation
2016, Advances in Pharmacology
Two decades have passed since the peptide, nociceptin/orphanin FQ (N/OFQ), and its cognate (NOP) receptor were discovered. Although NOP receptor activation causes a similar pattern of intracellular actions as mu-opioid (MOP) receptors, NOP receptor-mediated pain modulation in rodents are more complicated than MOP receptor activation. This review highlights the functional evidence of spinal, supraspinal, and systemic actions of NOP receptor agonists for regulating pain. In rodents, effects of the N/OFQ-NOP receptor system in spinal and supraspinal sites for modulating pain are bidirectional depending on the doses, assays, and pain modalities. The net effect of systemically administered NOP receptor agonists may depend on relative contribution of spinal and supraspinal actions of the N/OFQ-NOP receptor signaling in rodents under different pain states. In stark contrast, NOP receptor agonists produce only antinociception and antihypersensitivity in spinal and supraspinal regions of nonhuman primates regardless of doses and assays. More importantly, NOP receptor agonists and a few bifunctional NOP/MOP receptor agonists do not exhibit reinforcing effects (abuse liability), respiratory depression, itch pruritus, nor do they delay the gastrointestinal transit function (constipation) in nonhuman primates. Depending upon their intrinsic efficacies for activating NOP and MOP receptors, bifunctional NOP/MOP receptor agonists warrant additional investigation in primates regarding their side effect profiles. Nevertheless, NOP receptor-related agonists display a much wider therapeutic window as compared to that of MOP receptor agonists in primates. Both selective NOP receptor agonists and bifunctional NOP/MOP receptor agonists hold great potential as effective and safe analgesics without typical opioid-associated side effects in humans.
Characterization of nociceptive response to chemical, mechanical, and thermal stimuli in adolescent rats with neonatal dopamine depletion
2015, Neuroscience
Rats with dopamine depletion caused by 6-hydroxydopamine (6-OHDA) treatment during adulthood and the neonatal period exhibit akinetic motor activity and spontaneous motor hyperactivity during adolescence, respectively, indicating that the behavioral effects of dopamine depletion depend on the period of lesion development. Dopamine depletion during adulthood induces hyperalgesic response to mechanical, thermal, and/or chemical stimuli, whereas the effects of neonatal dopamine depletion on nociceptive response in adolescent rats are yet to be examined. The latter aspect was addressed in this study, and behavioral responses were examined using von-Frey, tail flick, and formalin tests. The formalin test revealed that rats with neonatal dopamine depletion exhibited a significant increase in nociceptive response during interphase (6–15 min post formalin injection) and phase 2 (16–75 min post formalin injection). This increase in nociceptive response to the formalin injection was not reversed by pretreatment with methamphetamine, which ameliorates motor hyperactivity observed in adolescent rats with neonatal 6-OHDA treatment. The von-Frey filament and tail flick tests failed to reveal significant differences in withdrawal thresholds between neonatal 6-OHDA-treated and vehicle-treated rats. The spinal neuronal response to the formalin injection into the rat hind paw was also examined through immunohistochemical analysis of c-Fos protein. Significantly increased numbers of c-Fos-immunoreactive cells were observed in laminae I–II and V–VI of the ipsilateral spinal cord to the site of the formalin injection in rats with neonatal dopamine depletion compared with vehicle-treated rats. These results suggest that the dopaminergic neural system plays a crucial role in the development of a neural network for tonic pain, including the spinal neural circuit for nociceptive transmission, and that the mechanism underlying hyperalgesia to tonic pain is not always consistent with that of spontaneous motor hyperactivity induced by neonatal dopamine depletion.
Paclitaxel-induced hyperalgesia modulates negative affective component of pain and NR1 receptor expression in the frontal cortex in rats
2014, Neuroscience Research
Citation Excerpt :
A nociceptive score was calculated for each 5 min block during the 70 min period based on the time spent in each of the following four behavioral categories: (0) full weight on the injected paw; (1) reduced weight on the injected paw; (2) elevation of the injected paw; (3) licking, biting, and shaking of the injected paw. Then the weighted nociceptive score revealed the formalin nociceptive score (Abbott et al., 1995; Coderre et al., 1993; Noda et al., 2003; Zhu et al., 1997). CPA testing was conducted as described previously (Li et al., 2009; Tanimoto et al., 2003; Watanabe et al., 2002).
Paclitaxel, one of the chemotherapeutic agents clinically used to treat several types of cancer, produces side effects such as peripheral neuropathy, sensory abnormalities, and hyperalgesia. Since hyperalgesia remains after cessation of paclitaxel therapy and becomes chronic, we hypothesize that alteration in memory and the cognitive process of pain underlies hyperalgesia. To test this hypothesis, we examined whether drug-induced hyperalgesia alters the affective component of pain and the NMDA-NR1 and mGluR1 receptors as a mediator for signal transmission and memory of pain. Mechanical sensitivity was measured by von Frey filament test after intraperitoneal injection of paclitaxel in rats. Paclitaxel-induced hyperalgesia was confirmed over almost the entire 14-day period of observation after the treatment. The effect of paclitaxel-induced hyperalgesia on the affective component of pain was assessed using pain-induced place aversion. The formalin-induced conditioned place aversion was completely abolished in the paclitaxel-treated rats. Immunoblot analysis of NR1 and mGluR1 protein levels in various brain regions was performed after paclitaxel treatment. Treatment reduced only the NR1 expression within the frontal cortex. These results suggest that the hypofunction of memory processes with the reduced NMDA receptors in the frontal cortex might be involved in the expression of abnormal emotional behaviors accompanied by hyperalgesia.
The role of nociceptin and dynorphin in chronic pain: Implications of neuro-glial interaction
2011, Neuropeptides
Citation Excerpt :
In Freund’s adjuvant-induced monoarthritis rat model, NOP receptor agonists, such as NOC and PheΨ injected i.c.v. after morphine induced an immediate and short-lived reversal of morphine’s effect (Bertorelli et al., 1999). In a formalin-induced model of inflammation, i.c.v. administration of NOC together with opioid receptor agonists, such as morphine, endomorphin-1, DSLET or U50,488H, attenuated analgesia induced by MOP and KOP, but not DOP receptor-mediated analgesia (Wang et al., 1999b; Zhu et al., 1997). These effects contrast the supraspinal effects in which NOC antagonized the effect of opioids (Wang et al., 1999).
Nociceptin-opioid peptide (NOP) receptor, also known as opioid receptor like-1 (ORL1), was identified following the cloning of the kappa-opioid peptide (KOP) receptor, and the characterization of these receptors revealed high homology. The endogenous ligand of NOP, nociceptin (NOC), which shares high homology to dynorphin (DYN), was discovered shortly thereafter, and since then, it has been the subject of several investigations. Despite the many advances in our understanding of the involvement of NOC and DYN systems in pain, tolerance and withdrawal, the precise function of these systems has not been fully characterized. Here, we review the recent literature concerning the distribution of the NOC and DYN systems in the central nervous system and the involvement of these systems in nociceptive transmission, especially under chronic pain conditions. We discuss the use of endogenous and exogenous ligands of NOP and KOP receptors in pain perception, as well as the potential utility of NOP ligands in clinical practice for pain management. We also discuss the modulation of opioid effects by NOC and DYN. We emphasize the important role of neuro–glial interactions in the effects of NOC and DYN, focusing on their presence in neuronal and non-neuronal cells and the changes associated with chronic pain conditions. We also present the dynamics of immune and glial regulation of neuronal functions and the importance of this regulation in the roles of NOC and DYN under conditions of neuropathic pain and in the use of drugs that alter these systems for better control of neuropathic pain.
Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain
2009, Life Sciences
It has been well documented that ventrolateral periaqueductal gray (vlPAG) matter is a crucial component of the descending pain modulatory system in the chronic pain condition. The aim of the present study was to identify the role of the vlPAG Nociceptin/Orphanin FQ/NOP receptor system in allodynia, a nociceptive behavioral response associated with chronic pain.
We used two animal models of persistent pain: chronic constriction injury (CCI) and inflammation induced by carrageenan. In each, Nociceptin/Orphanin FQ transmission was abolished using UFP-101, a selective NOP receptor antagonist, which was injected into the vlPAG at a dose of 18 µg/1 µl/rat.
We found that treatment with the NOP antagonist reversed the decrease in allodynic threshold in CCI rats fourteen days after the ligature, which was the timepoint of the greatest reduction in threshold. Moreover, UFP-101 administered immediately prior to or 2 h after intra plantar (i.pl.) carrageenan injection prevented or reversed, respectively, allodynic behavior in rats with inflammation.
Our findings support the hypothesis that the endogenous Nociceptin/Orphanin FQ/NOP receptor system is tonically active at the vlPAG level during neuropathic states or carrageenan inflammation.
Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats
2009, Pain
Citation Excerpt :
N/OFQ–NOP receptor system has a distinct pharmacological profile in pain control. N/OFQ has controversial effects in different somatic pain models, depending on the site of injection or the pain paradigm considered, even though a supraspinal hyperalgesic and spinal analgesic effects are broadly accepted [29,38,53,56]. The role of endogenous N/OFQ at spinal level in pain regulation is conflicting.
Nociceptin/orphanin FQ (N/OFQ) and its NOP receptors are present in the central nervous system and in the periphery playing important roles in the modulation of gastrointestinal functions and pain. The aim of this study was to investigate the role of central and peripheral N/OFQ–NOP receptor system in the nociceptive response to colorectal distension (CRD) in basal condition and in two models of gut hypersensitivity triggered by both inflammation and stress. Male Wistar rats were tested in basal and in post-inflammatory conditions, i.e., 5 days after IC TNBS instillation (80 mg/Kg) and received N/OFQ (2 nmol/Kg IP), UFP-101 (a selective NOP receptor antagonist, 10 nmol/Kg IP), N/OFQ+UFP-101, N/OFQ (0.5 nmol/rat ICV) or vehicle. Female rats were tested in basal and after partial restraint stress receiving the same pharmacological treatment. CRD was performed using barostat and abdominal contractions were recorded by electromyography. In basal condition, N/OFQ, ICV and IP injected, did not modify basal visceral sensitivity. Both in TNBS and stress-induced hyperalgesia, IP but not ICV injection of N/OFQ significantly decreased the number of abdominal contractions. Peripheral injection of UFP-101 antagonized N/OFQ effect. Moreover, in post-inflammatory colitis, UFP-101, injected alone, exacerbated visceral hyperalgesia to CRD compared with vehicle. These findings indicate that in rats, N/OFQ, only peripherally injected, reduces visceral hypersensitivity triggered by inflammation or stress without affecting basal sensitivity. N/OFQ visceral anti-hyperalgesic effect involves peripheral NOP receptors. In a post-inflammatory, but not in an acute stress colitis model, N/OFQergic system is endogenously activated.

View all citing articles on Scopus

View full text

Orphanin FQ potentiates formalin-induced pain behavior and antagonizes morphine analgesia in rats

Abstract

Section snippets

Acknowledgements

Pain

Pain

Neurosci. Lett.

Neuroscience

Eur. J. Pharmacol.

Neuropharmacology

Mol. Brain Res.

Pain

Changes in nociception after lesions of descending serotoninergic pathways induced with 5,6-dihydroxytryptamine. Different effects in the formalin and tail-flick tests

Neuropharmacology

Nociceptin can modulate evoked enkephalin release from the myenteric plexus

Soc. Neurosci. Abstr.